Product Description
for the treatment of critical limb ischemia (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25190335/)
Mechanisms of Action: Gene Therapy, C-Met
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AnGes
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Atherosclerosis
Phase 2: Peripheral Vascular Diseases|Peripheral Arterial Disease|Leg Ulcer|Foot Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AG-CLI-0206-LTFU | N/A |
Completed |
Other |
2020-01-10 |
2020-03-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| AG-CLTI-0211 | P2 |
Unknown status |
Leg Ulcer|Peripheral Arterial Disease|Foot Ulcer |
2022-07-01 |
50% |
2023-12-05 |
Primary Endpoints|Treatments|Trial Status |
| AG-CLI-0209 | P2 |
Completed |
Peripheral Arterial Disease|Peripheral Vascular Diseases |
2018-03-31 |
2019-03-20 |
Treatments |
|
| JapicCTI-195088 | P3 |
Unknown |
Unknown |
2021-12-31 |
|||
| 2016-003491-41 | P3 |
Completed |
Unknown |
2020-01-10 |
2025-05-06 |
Treatments |
|
| 2014-001129-34 | P3 |
Terminated |
Unknown |
2019-06-15 |
2022-03-13 |
Treatments |
|
| AGILITY | P3 |
Terminated |
Unknown |
2016-11-28 |
2019-08-14 |
||
| JapicCTI-050186 | P3 |
Completed |
Atherosclerosis |
None |
|||
| JapicCTI-050187 | P3 |
Completed |
Unknown |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/26/2021 |
News Article |
Hepatocyte Growth Factor Pipeline Report, H2 2020 Edition - ResearchAndMarkets.com |
|
04/14/2021 |
News Article |
Gene Therapy R&D and Revenue Forecasts 2020-2030 |
|
10/15/2020 |
News Article |
AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene® in Turkey |
|
09/30/2019 |
News Article |
Gene Therapy Market (3rd Edition), 2019-2030 |